Emergent BioSolutions Inc. (EBS)
| Market Cap | 231.24M -50.7% |
| Revenue (ttm) | 770.20M -9.6% |
| Net Income | -176.80M |
| EPS | -3.39 |
| Shares Out | 51.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,402 |
| Open | 4.500 |
| Previous Close | 4.590 |
| Day's Range | 4.460 - 4.540 |
| 52-Week Range | 4.360 - 14.060 |
| Beta | 2.36 |
| Analysts | Strong Buy |
| Price Target | 11.00 (+143.9%) |
| Earnings Date | Aug 5, 2026 |
About EBS
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma ... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for EBS stock is "Strong Buy." The 12-month stock price target is $11.0, which is an increase of 143.90% from the latest price.
News
EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions
Emergent BioSolutions cut its FY2026 adjusted EBITDA outlook to $130-$150 million from $155-$175 million amid continued NARCAN pricing and margin pressure, with NARCAN gross margin having fallen to 1...
Emergent BioSolutions price target lowered to $10 from $12 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Emergent BioSolutions (EBS) to $10 from $12 and keeps a Buy rating on the shares. The company reported a revenue beat and…
Emergent BioSolutions Earnings Call Transcript: Q2 2026
Q2 2026 results exceeded expectations with strong MCM revenue and disciplined execution, but naloxone market competition led to a downward revision in full-year guidance and a $191 million non-cash impairment. Restructuring actions target $40 million in annualized savings.
Emergent BioSolutions Earnings release: Q2 2026
Emergent BioSolutions released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Emergent BioSolutions Slides: Q2 2026
Emergent BioSolutions has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Emergent BioSolutions Quarterly report: Q2 2026
Emergent BioSolutions has published its Q2 2026 quarterly earnings report on August 5, 2026.
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as all...
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2026.
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
GAITHERSBURG, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 5, 2026, at 5:00 p.m. eastern time to discuss the financial...
Emergent BioSolutions awarded $52.7M contract modification
Emergent BioSolutions (EBS) announced it has been awarded a contract modification valued at $52.7M from the Administration for Strategic Preparedness and Response, or ASPR, at the United States Depart...
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
GAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for St...
BioMendics Receives FDA Fast Track Designation for BM-3103 (TolaSure® Gel™) for Epidermolysis Bullosa Simplex
AKRON, Ohio--(BUSINESS WIRE)-- #BIO2026--BioMendics, LLC, a clinical-stage biotechnology company developing innovative therapies for rare genetic skin disorders, today announced that the U.S. Food and...
Emergent BioSolutions Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company leads in biodefense and opioid overdose treatments, reporting a successful turnaround with improved EBITDA, cash flow, and debt reduction. Growth is driven by product innovation, international expansion, and major government contracts, with a strong focus on R&D and capital efficiency.
Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources Efforts focus on increasing awareness...
Emergent BioSolutions Transcript: Jefferies Global Healthcare Conference 2026
The company highlighted its leadership in biodefense and opioid overdose solutions, reporting a successful turnaround with improved EBITDA, reduced debt, and strong Q1 2026 results. Growth is driven by international expansion, new contracts, product innovation, and a robust R&D pipeline.
Emergent BioSolutions awarded $64.5M HHS contract modification
Emergent BioSolutions (EBS) announced it has been awarded a contract modification valued at approximately $64.5M from the Administration for Strategic Preparedness and Response, or ASPR, a division of...
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Ad...
Emergent BioSolutions to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's senior management team will participate in the following invest...
Emergent BioSolutions receives Saudi approval for ACAM2000 vaccine
Emergent BioSolutions (EBS) announced that the Saudi Food and Drug Authority has approved the registration of ACAM2000 for the prevention of smallpox and mpox disease in individuals determined to be…
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the regist...
Hantavirus cases spark surge in pharma and biotech stocks — here's why
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.
Emergent BioSolutions Earnings Call Transcript: Q1 2026
Q1 2026 revenue and EBITDA exceeded expectations, driven by strong MCM and naloxone performance, international expansion, and operational efficiency. Debt reduction, refinancing, and new partnerships strengthened the financial position, with full-year guidance maintained.
Emergent BioSolutions Earnings release: Q1 2026
Emergent BioSolutions released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Emergent BioSolutions Slides: Q1 2026
Emergent BioSolutions has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Emergent BioSolutions Quarterly report: Q1 2026
Emergent BioSolutions has published its Q1 2026 quarterly earnings report on April 30, 2026.